Home Reports Studies and Analyses Content

Newly incarcerated have 1 percent acute hepatitis C prevalence

next article

20.03.2013

Screening of new inmates with IV drug history could identify thousands of new HCV cases annually

A study published in the March issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, estimates that the prevalence of acute hepatitis C virus (HCV) infection is nearly one percent among newly incarcerated inmates with a history of recent drug use.

Findings suggest that systematic screening of intravenous (IV) drug users who are new to the prison system could identify more than 7,000 cases of HCV across the U.S. annually—even among asymptomatic inmates.

According to the National Institute of Allergy and Infectious Diseases Health—the funding organization for this current study—chronic HCV affects 180 million people worldwide, with more than 4 million cases in the U.S. Studies have shown that most IV drug users acquire HCV with in the first year of risky injection habits and in the U.S. this population accounts for 46% of symptomatic acute infections. Due to past injection drug use, incarcerated inmates have HCV infection rates ranging from 25% to 41%—roughly 20 times higher than the general population.

"While the Centers for Disease Control and Prevention (CDC) recommend more vigilant surveillance of at risk populations, many healthcare programs in correctional facilities do not routinely screen for HCV," comments Dr. Arthur Kim with the Division of Infectious Diseases at Massachusetts General Hospital and Harvard University Center for AIDS Research in Boston. "Our study investigated whether the implementation of a low-cost, systematic screening process for high-risk behavior could uncover more asymptomatic acute HCV cases among newly incarcerated individuals who recently used injection drugs."

Between October 2006 and March 2008 the team assessed the health of 6,342 inmates with 55% of those screened for HCV. Of the 3470 inmates who were screened 24% were African-America, 50% Caucasian, and 22% Hispanic. Results show that 21% of the 171 high-risk inmates had acute HCV. Inmates who were diagnosed with HCV had a mean age of 29 years and 63% were female. This investigation found 91% of those with acute HCV were Caucasian, while no African-Americans were diagnosed with this disease.

Further analysis found that about one out of every hundred inmates screened were diagnosed with acute HCV infection. Dr. Kim concludes, "Based on estimates that 700,000 individuals enter the prison system each year, about 7,000 new cases of acute HCV infection would be identified if screening strategies were systematically adopted. Further validation of our screening approach in healthcare settings such as detoxification programs or emergency rooms is warranted. Adoption of such screening programs in high-risk populations would provide an opportunity for greater diagnosis and prevention of HCV."

To request a copy of the study, please contact sciencenewsroom@wiley.com.

Full citation: "A Simple Strategy to Identify Acute HCV Infection Among Newly Incarcerated Injection Drug Users." Arthur Y. Kim, Ellen H. Nagami, Christopher E. Birch, Melinda J. Bowen, Georg M. Lauer and Barbara H. McGovern. Hepatology; (DOI: 10.1002/hep.26113); Print Issue Date: March, 2013.

URL: http://doi.wiley.com/10.1002/hep.26113

Author Contact: To arrange an interview with Dr. Kim, please contact Michael Morrison at MDMORRISON@partners.org.

About the Journal

Hepatology is the premier publication in the field of liver disease, publishing original, peer-reviewed articles concerning all aspects of liver structure, function and disease. Each month, the distinguished Editorial Board monitors and selects only the best articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism. Hepatology is published on is published by Wiley on behalf of the American Association for the Study of Liver Diseases (AASLD). For more information, please visit http://wileyonlinelibrary.com/journal/hep.

About Wiley

Wiley is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.

Founded in 1807, John Wiley & Sons, Inc. (NYSE: JWa, JWb), has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia.

Dawn Peters | Source: EurekAlert!
Further information: www.wiley.com

next article